Lisa Weiss, PA, medical director of the RAPID Conference, explains what makes this immunodermatology meeting stand out for dermatology clinicians. She discusses why up-to-date clinical content and a…
Although it is one of the most common dermatologic diseases, atopic dermatitis has not had many targeted treatments…until now! The list of treatments is growing, and approaches to…
Atopic dermatitis data have been spread across surveys, claims studies, and smaller data sets. Tenesha Wallace Hood, MA, director of healthcare provider engagement at the National Eczema Association…
Aaron S. Farberg, MD, chief medical officer at Bare Dermatology in Dallas, spoke with HCPLive at the 2026 Fall Clinical Dermatology Conference about how precision medicine is changing…
Topical corticosteroids remain a cornerstone of atopic dermatitis care, but steroid phobia and a growing roster of nonsteroidal agents are reshaping how clinicians use them. On this episode…
Why can’t some Medicare patients get advanced therapy for skin disease, even after they’ve failed standard topicals? In this interview from the 2026 Horizons in Advanced Practice meeting…
Exosomes in dermatology are moving closer to a regulatory pathway, and a new remibrutinib label update is changing how clinicians approach symptomatic dermographism. Todd Schlesinger, MD, shares the…
Atopic dermatitis late-breakers from EADV 2026 in Vienna are the focus of this Dermatology Times interview with Christopher Bunick, MD, PhD, associate professor of dermatology at Yale School…
Atopic dermatitis (AD) affects more than 31 million people in the United States, about 1 in 10, and it remains underestimated and underappreciated for its impact. The State…